CRF type I receptor-deficient mice exhibit a pronounced pituitary- adrenal response to local inflammation

Endocrinology

Volumn 140, Issue 2, 1999, Pages 1013-1017

  Turnbull, Andrew V ^a   Smith, George W ^a,b   Lee, Soon ^a   Vale, Wylie W ^a   Lee, Kuo Fen ^a   Rivier, Catherine ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTERONE; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; TURPENTINE;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; CORTICOTROPIN BLOOD LEVEL; FEMALE; HORMONAL REGULATION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032933186     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.2.6675     Document Type: Article

References (30)

1. 1. Vale W, Speiss J, Rivier C, Rivier J 1981 Characterization of a 41-amino acid residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and β-endorphin. Science 213:1394-1397
2. 2. Vale W, Vaughan J, Perrin M H 1997 Corticotropin-releasing factor (CRF) family of ligands and their receptors. The Endocrinologist 7:3S-9S
3. 3. Turnbull A V, Rivier C 1997 Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein and related peptides. Proc Soc Exp Biol Med 215:1-10
4. 4. Schulz D W, Mansbach R S, Sprouse J, Braselton J P, Collins J, Corman M, Dunaiskis A, Faraci S, Schmidt A W, Seeger T, Seymour P, Tingley F D, Winston E N, Chen Y L, Heym J 1996 CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci USA 93:10477-10482
5. 5. Webster E L, Lewis D B, Torpy D J, Zachman E K, Rice K C, Chrousos G P 1996 In vivo characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology 137:5745-5750
6. 6. Bornstein S R, Webster E L, Torpy D J, Richman S J, Mitsiades N, Ingel M, Lewis D B, Rice K C, Joost H G, Tsokos M, Chrousos G P 1998 Chronic effects of a nonpeptide corticotropin-releasing hormone type I receptor antagonist on pituitary-adrenal function, body weight, and metabolic regulation. Endocrinology 139:1546-1555
7. 7. Mansbach R S, Brooks E N, Chen Y L 1997 Antidepressant effects of CP-154,526, a selective CRF1 receptor antagonist. Eur J Pharmacol 323:21-26
8. 8. Baram T Z, Chalmers D T, Chen C, Koutsoukos Y, De Souza E B 1997 The CRF1 receptor mediates the excitatory actions of corticotropin-releasing factor (CRF) in the developing rat brain: in vivo evidence using a novel,selective, non-peptide CRF receptor antagonist. Brain Res 770:89-95
9. 9. Smith G W, Aubry J M, Dellu F, Contarino A, Bilezikjian L M, Gold L H, Chen R, Marchuk Y, Hauser C, Bentley C A, Sawchenko P E, Koob G F, Vale W, Lee K F 1998 Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-102
10. 10. Timpl P, Spanagel R, Sillaber I, Kresse A, Reul J M, Stalla G K, Blanquet V, Steckler T, Holsboer F, Wurst W 1998 Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-6
11. 11. Muglia L, Jacobson L, Dikkes P, Majzoub J A 1995 Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 373:427-432
12. 12. Muglia L J, Jacobson L, Weninger S C, Luedke C E, Bae D S, Jeong K H, Majzoub J A 1997 Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest 99:2923-2929
13. 13. Antoni F A 1993 Vasopressinergic control of pititary adrenocorticotropin secretion comes of age. Front Neuroendocrinol 14:76-122
14. 14. Turnbull A V, Rivier C 1996 Corticotropin-releasing factor, vasopressin and prostaglandins mediate, and nitric oxide restrains, the HPA axis response to acute local inflammation in the rat. Endocrinology 137:455-463
15. 15. Turnbull A V, Pitossi F J, Lebrun J-J, Lee S, Meltzer J C, Nance D M, del Rey A, Besedovsky H O, Rivier C 1997 Inhibition of tumor necrosis factor-β (TNF-α) action within the central nervous system markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats. J Neurosci 17:3262-3273
16. 16. Vale W, Vaughan J, Yamamoto G, Bruhn T, Douglas C, Dalton D, Rivier C, Rivier J, Assay of corticotropin releasing factor, in Methods in Enzymology: Neuroendocrine Peptides, P.M. Conn, Editor. 1983, Academic Press: New York. p. 565-577.
17. 17. Turnbull A V, Vaughan J, Rivier J, Vale W, Rivier C 1999 Urocortin is not a significant regulator of intermittent electrofootshock-induced adrenocorticotropin secretion in the intact male rat. Endocrinology in press.
18. 18. Turnbull A V, Rivier C 1998 Intracereboventricular passive immunization II: Intracerebroventricular infusion of neuropeptide antisera can inhibit neuropeptide signaling in peripheral tissues. Endocrinology 139:128-136
19. 19. Gershenwald J E, Fong Y, Fahey T J, Calvano S E, Chizzonite R, Kilian P L, Lowry S F, Moldawer L L 1990 Interleukin-1 receptor blockade attenuates the host inflammatory response. Proc Natl Acad Sci USA 87:4966-4970
20. 20. Kozak W, Poli V, Soszynski D, Conn C A, Leon L R, Kluger M J 1997 Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. Am J Physiol 272:R621-R630
21. 21. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G 1994 Impaired immune and acute-phase responses in interleukin-6 deficient mice. Nature 368:339-342
22. 22. Zheng H, Fletcher D, Kozak W, Jiang M, Hofman K J, Conn C A, Soszynski D, Grabiec C, Trumbauer M E, Shaw A, Kostura M J, Stevens K, Rosen H, North R J, Chen H Y, Tocci M J, Kluger M J, Van der Ploeg L H T 1995 Resistance to fever induction and impaired acute-phase response in interleukin-1β-deficient mice. Immunity 3:9-19
23. 23. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, Nishihara M, Takahashi M, Iwakura Y 1998 Production of Mice Deficient in Genes for Interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 Receptor Antagonist Shows that IL-1 beta Is Crucial in Turpentine-induced Fever Development and Glucocorticoid Secretion. J Exp Med 187:1463-75
24. 24. Turnbull A V, Rivier C L 1999 Regulation of the hypothalamo-pituitary-adrenal (HPA) axis by cytokines: actions and mechanisms of action. Physiol Rev 79:1-71
25. 25. Ray D, Melmed S 1997 Pituitary cytokine and growth factor expression and action. Endocr Rev 18:206-228
26. 26. Turnbull A V, Brouwer S, Hopkins S J, Rothwell N J 1993 The involvement of endogenous glucocorticoids and interleukin-6 in the febrile response to localized inflammation. J Physiol 467:215P
27. 27. Pereda M P, Sauer J, Castro C P, Finkielman S, Stall G K, Holsboer F, Arzt E 1995 Corticotropin-releasing hormone differentially modulates the interleukin-1 system according to the level of monocyte activation by endotoxin. Endocrinology 136:5504-5510
28. 28. Salas M A, Brown O A, Perone M J, Castro M G, Goya R G 1997 Effect of corticotropin-releasing hormone precursor on interleukin-6 release by human mononuclear cells. Clin Immunol Immunopathol 85:35-39
29. 29. Tilg H, Dinarello C A, Mier J W 1997 IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today 18:428-432
30. 30. Karalis K, Sano H, Redwine J, Listwak S, Wilder R L, Chrousos G P 1991 Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254:421-423